BINSA, a bipartisan bill restricting US biotech deals with Chinese firms, is in limbo after failing to advance via the House Rules Committee. Sponsors include Reps. Moolenaar and Dingell.
After setting the industry ablaze last month, a bipartisan bill aimed at restricting US biotech companies from striking deals with Chinese counterparts …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Bipartisan Michigan lawmakers unveil a bill subjecting US-China biotech deals to outbound investment screening, citing national…
If enacted, BINSA would give lawmakers the right to monitor and restrict American companies from signing biotech and…
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing buyers and sellers to rethink…
At least 10 House lawmakers are backing a US trade panel’s probe of China’s biotech sector and related pricing practices,…
A key US House Republican urges Treasury to restrict US investment in China biotech, spotlighting Bristol Myers Squibb's Hengrui…
PhRMA and BIO mobilize against a wave of anti-China biotech bills in Congress as lawmakers move to curb US dealmaking with China.
Bipartisan Senate bill seeks to build vigilance around foreign companies making drugs in US
